Therapeutic Response

PD-L1 >= 1%, Wild type ALK, Wild type EGFR, and Wild type ROS1 status confers therapeutic sensitivity to Carboplatin in combination with Cemiplimab and Pemetrexed in patients with Non-Small Cell Lung Cancer.

Statements

Source and description

Libtayo (cemiplimab) [product information]. EMA. The European Medicines Agency (EMA) has authorized cemiplimab in combination with platinum-based chemotherapy for the first-line treatment of adult patients with NSCLC expressing PD-L1 (in >= 1% of tumor cells), with no EGFR, ALK, or ROS1 aberrations. This indication is specifically for patients who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or patients with metastatic NSCLC. This indication is based on Study 16113, a randomized, multi-center, double-blind, active-controlled trial. The chemotherapy used in this study consisted of either carboplatin or cisplatin in combination with paclitaxel or pemetrexed.